Ann Surg Oncol

1. SHIMIZU H, Kurashima K, Fukami T, Shiozaki A, et al
   Functional Analysis and Clinical Significance of Glutaredoxin 2 in Colon Cancer.
   Ann Surg Oncol. 2025 Jun 5. doi: 10.1245/s10434-025-17404.
   

   >> Share

   
   
2. TSAGKALIDIS V, Handorf EA, Bates BA, Brauer DG, et al
   ASO Visual Abstract: Estimating the Survival Impact of Curative-Intent Liver Therapies for Colorectal Cancer Liver Metastases.
   Ann Surg Oncol. 2025 Jun 5. doi: 10.1245/s10434-025-17620.
   

   >> Share

   
   
3. SHIMIZU H, Kurashima K, Fukami T, Shiozaki A, et al
   ASO Visual Abstract: Functional Analysis and Clinical Significance of Glutaredoxin 2 in Colon Cancer.
   Ann Surg Oncol. 2025 Jun 3. doi: 10.1245/s10434-025-17582.
   

   >> Share

   
   
4. TAQI K, Icchhpuniani S, Stockley C, Elmi Assadzadeh G, et al
   ASO Visual Abstract: Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS & HIPEC) and Liver-Directed Therapy for Synchronous Peritoneal and Liver Metastatic Colorectal Cancer: A Systematic Review with Meta-analysis.
   Ann Surg Oncol. 2025 Jun 2. doi: 10.1245/s10434-025-17569.
   

   >> Share

   
   
5. LOEHRER AP, Wang Q, O'Malley AJ, Wong SL, et al
   ASO Visual Abstract: Influence of Medicaid Expansion on Rural Medicare Beneficiaries Undergoing Colon-Cancer-Directed Surgery in the United States.
   Ann Surg Oncol. 2025 May 31. doi: 10.1245/s10434-025-17469.
   

   >> Share

   
   
6. RAICHURKAR P, Brown KGM, White K, Koh CE, et al
   Undergoing Cytoreductive Surgery for Colorectal Peritoneal Metastases: A Qualitative Exploration of the Lived Experiences of Patients and Carers.
   Ann Surg Oncol. 2025;32:5042-5050.
   

   >> Share

   
   
7. PEREZ RO, Vailati BB, Sao Juliao GP, Mazzucato F, et al
   The Landmark Series: Organ Preservation in Rectal Cancer-The Watch and Wait Strategy.
   Ann Surg Oncol. 2025;32:4945-4956.
   

   >> Share

   
   
8. BUNJO Z, Sammour T
   The Landmark Series: Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
   Ann Surg Oncol. 2025;32:4935-4944.
   

   >> Share

   
   
9. ZIVANOV CN, Kau NS, Nalluri-Butz H, Oduyale OK, et al
   Nonoperative Management of Rectal Cancer: Is "Near-Complete" Response Safe to Surveil?
   Ann Surg Oncol. 2025;32:4922-4930.
   

   >> Share

   
   

   
   BMC Cancer

10. WANG Y, Lu J, Huang D, Chen P, et al
    Explosive tumor growth in a patient with colon cancer is associated with reduced neoantigen levels and decreased interferon-gamma (IFN-gamma) signaling.
    BMC Cancer. 2025;25:1005.
    

    >> Share

    
    
11. VAHED IE, Moshgelgosha M, Kor A, Minadi M, et al
    The role of Adiponectin and Leptin in Colorectal Cancer and Adenoma: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:968.
    

    >> Share

    
    
12. MA A, Zhai C, He Q, Wang W, et al
    ENTR1 affects the progression of colon cancer by regulating energy metabolism under the influence of glycolysis.
    BMC Cancer. 2025;25:992.
    

    >> Share

    
    
13. SABERPOUR M, Maqsoodi R, Bakhshi B
    Anti-cancer properties of chitosan /Lactobacillus acidophilus secretome nanoparticle on signaling pathways of colorectal cancer in colon adenocarcinoma (Caco-2) cell line.
    BMC Cancer. 2025;25:983.
    

    >> Share

    
    
14. ZENG Z, Ke Y, Huang F, Li H, et al
    Targeting INF2 with DiosMetin 7-O-beta-D-Glucuronide: a new stratagem for colorectal cancer therapy.
    BMC Cancer. 2025;25:982.
    

    >> Share

    
    
15. XIE X, Wang W, Zhang H, Zhao S, et al
    Cholesterol-induced colorectal cancer progression and its mitigation through gut microbiota remodeling and simvastatin treatment.
    BMC Cancer. 2025;25:977.
    

    >> Share

    
    

    
    BMC Gastroenterol

16. LV J, Chen Q, Yang L, Guan J, et al
    Comparative serum imidazole propionate profiling in colorectal adenoma and cancer by UPLC-MS/MS.
    BMC Gastroenterol. 2025;25:426.
    

    >> Share

    
    

    
    Cancer Lett

17. SUN Z, Wu R, Liang X, Shi T, et al
    MLCK inhibition induces synthetic lethality in MYC-driven cancer.
    Cancer Lett. 2025;625:217803.
    

    >> Share

    
    
18. MIDDE A, Arri N, Kristian T, Mukherjee S, et al
    Corrigendum to "Targeting mitochondrial ribosomal protein expression by andrographolide and melatonin for colon cancer treatment" [Cancer Lett. 619 (2025) 1-11 217647].
    Cancer Lett. 2025 May 30:217784. doi: 10.1016/j.canlet.2025.217784.
    

    >> Share

    
    

    
    Gastroenterology

19. LIU J
    Is the Molecular Classification of ERBB2 in Stage III Colon Cancer Clinically Ready?
    Gastroenterology. 2025 Jun 3:S0016-5085(25)00839.
    

    >> Share

    
    

    
    Gastrointest Endosc

20. CHANDAN S
    Endoscopic Approaches to Reduce the Incidence of Interval Colon Cancer.
    Gastrointest Endosc. 2025 May 28:S0016-5107(25)01701.
    

    >> Share

    
    

    
    Gut

21. SOUNDARARAJAN R, Halade G, Yeatman TJ
    Response to the letter to the editor 'revisiting lipid dysregulation in colorectal cancer: critical appraisal of pro-inflammatory bias and therapeutic implications'.
    Gut. 2025 Jun 4:gutjnl-2025-335452. doi: 10.1136/gutjnl-2025-335452.
    

    >> Share

    
    
22. ZHANG Y, Song W, Zhou L, Wei S, et al
    Bacteria-metabolite butyrate boosts anti-PD1 efficacy in colorectal cancer patient-derived organoids through activating autologous tumour-infiltrating GNLY (+)CD8(+) T cells.
    Gut. 2025 Jun 1:gutjnl-2025-335306. doi: 10.1136/gutjnl-2025-335306.
    

    >> Share

    
    

    
    Int J Cancer

23. KORSGAARD U, Kristensen MP, Garcia-Rodriguez JL, Kjaer-Frifeldt S, et al
    The prognostic potential of RNA in stage II colon cancer: Insights from a screened multicenter population-based cohort study.
    Int J Cancer. 2025 Jun 6. doi: 10.1002/ijc.35507.
    

    >> Share

    
    

    
    Int J Colorectal Dis

24. HARA K, Chikaishi W, Yamada Y, Fujii H, et al
    Geriatric 8 score as a prognostic factor of the efficacy and safety of oxaliplatin-based chemotherapy in elderly patients with metastatic colorectal cancer.
    Int J Colorectal Dis. 2025;40:132.
    

    >> Share

    
    

    
    J Natl Cancer Inst

25. 
    Correction to: Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    J Natl Cancer Inst. 2025 May 30:djaf124. doi: 10.1093.
    

    >> Share

    
    
26. OVEISI N, Sayre EC, Brotto LA, Cheng V, et al
    Sexual health outcomes after colorectal cancer diagnosis in females: a population-based cohort study.
    J Natl Cancer Inst. 2025 Jun 1:djaf120. doi: 10.1093.
    

    >> Share

    
    

    
    J Surg Oncol

27. EMILE SH, Horesh N, Garoufalia Z, Gefen R, et al
    Development and Validation of a Predictive Score for Preoperative Detection of Lymphovascular Invasion in Rectal Cancer.
    J Surg Oncol. 2025;131:1081-1089.
    

    >> Share

    
    
28. HENDRICK LE, Naffouje S, Imanirad I, Pereira AL, et al
    Incomplete?Resection?Is?Twice as Likely in Locally Advanced Mucinous?Compared to?Nonmucinous?Rectal Adenocarcinoma: A National Propensity-Matched Analysis.
    J Surg Oncol. 2025;131:1090-1100.
    

    >> Share

    
    
29. NADARAJAN AR, Krishnan Nair C, Muralee M, Wagh MS, et al
    Outcomes of Minimally Invasive Rectal Cancer Resection: Insights From a Resource-Limited Setting.
    J Surg Oncol. 2025;131:1101-1109.
    

    >> Share

    
    
30. BALLAL DS, Saklani AP
    Evidence-Based De-Escalation of Radiotherapy in Locally Advanced Rectal Cancer.
    J Surg Oncol. 2025;131:983-987.
    

    >> Share

    
    
31. BAKILLAH E, Rosenthal JW, Syvyk S, Wirtalla C, et al
    The Burden of Colorectal Cancer Treatment on Quality of Life: A Paired Longitudinal Analysis of Medicare Advantage Enrollees.
    J Surg Oncol. 2025 Jun 2. doi: 10.1002/jso.28161.
    

    >> Share

    
    

    
    Lancet Oncol

32. GILBERT A, Adams R, Webster J, Gilbert DC, et al
    Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial.
    Lancet Oncol. 2025;26:707-718.
    

    >> Share

    
    

    
    N Engl J Med

33. COURNEYA KS, Vardy JL, O'Callaghan CJ, Gill S, et al
    Structured Exercise after Adjuvant Chemotherapy for Colon Cancer.
    N Engl J Med. 2025 Jun 1. doi: 10.1056/NEJMoa2502760.
    

    >> Share

    
    
34. ELEZ E, Yoshino T, Shen L, Lonardi S, et al
    Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.
    N Engl J Med. 2025 May 30. doi: 10.1056/NEJMoa2501912.
    

    >> Share

    
    

    
    Oncogene

35. GUO ST, Jiang CC, Wang GP, Li YP, et al
    Correction: MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.
    Oncogene. 2025 Jun 3. doi: 10.1038/s41388-025-03446.
    

    >> Share

    
    
36. GU J, Xu X, Li X, Yue L, et al
    Correction: Tumor-resident microbiota contributes to colorectal cancer liver metastasis by lactylation and immune modulation.
    Oncogene. 2025 Jun 2. doi: 10.1038/s41388-025-03439.
    

    >> Share

    
    
37. QU S, Feng B, Xing M, Qiu Y, et al
    PRMT5 K240lac confers ferroptosis resistance via ALKBH5/SLC7A11 axis in colorectal cancer.
    Oncogene. 2025 May 30. doi: 10.1038/s41388-025-03457.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

38. IGUCHI E, Takai A, Oe N, Fujii Y, et al
    Epithelial Regnase-1 inhibits colorectal tumor growth by regulating IL-17 signaling via degradation of NFKBIZ mRNA.
    Proc Natl Acad Sci U S A. 2025;122:e2500820122.
    

    >> Share

    
    

    
    World J Surg

39. GIANNONE F, Sangiuolo F, Cassese G, Palucci M, et al
    The Impact of KRAS Status on Long-Term Outcomes After Thermal Ablation and Hepatic Resection for Liver-Only Colorectal Metastases: A New Clue for Tailoring Surgical Strategy on Tumor Biology?
    World J Surg. 2025;49:1573-1582.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share